| Abstrakt: |
A recent report from Harvard University T.H. Chan School of Public Health discusses the potential use of metabolomic and lipidomic biomarkers for breast cancer diagnosis and treatment. Breast cancer is the most common cancer among women in the United States, and early detection and treatment are crucial for improving outcomes. The current methods of detection, such as mammography and ultrasonography, have limitations in sensitivity and specificity. Therefore, the development of advanced biomarkers could enhance early detection, monitoring of disease progression, and personalized treatment plans. The researchers emphasize the importance of pursuing novel biomarkers to advance breast cancer diagnosis and treatment. [Extracted from the article] |
